相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts
Priyanka Sharma et al.
CLINICAL CANCER RESEARCH (2017)
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2-breast cancer: results from two prospective trials
M. V. Dieci et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy
Balazs Acs et al.
DIAGNOSTIC PATHOLOGY (2017)
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer
Maddalena Barba et al.
BMC CANCER (2017)
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer
Z. A. Nahleh et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy
Patrizia Vici et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
Roberta Visconti et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial
Pin Zhang et al.
ONCOTARGET (2016)
Preoperative Carboplatin-Paclitaxel-Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study
Valentina Guarneri et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Strategies for developing Ki67 as a useful biomarker in breast cancer
Carsten Denkert et al.
BREAST (2015)
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
William M. Sikov et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)
G. von Minckwitz et al.
ANNALS OF ONCOLOGY (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gunter von Minckwitz et al.
LANCET ONCOLOGY (2014)
Both Carboplatin and Bevacizumab Improve Pathological Complete Remission Rate in Neoadjuvant Treatment of Triple Negative Breast Cancer: A Meta-Analysis
Xiao-song Chen et al.
PLOS ONE (2014)
Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy
Kunpeng Wu et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2014)
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
B. Gerber et al.
ANNALS OF ONCOLOGY (2013)
The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients
Judith Hurley et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Neoadjuvant, Anthracycline-Free Chemotherapy with Carboplatin and Docetaxel in Triple-Negative, Early-Stage Breast Cancer: A Multicentric Analysis of Feasibility and Rates of Pathologic Complete Response
Peter Kern et al.
CHEMOTHERAPY (2013)
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
Hiroko Masuda et al.
CLINICAL CANCER RESEARCH (2013)
Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer
Gunter von Minckwitz et al.
CLINICAL CANCER RESEARCH (2013)
Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy
Nehmat Houssami et al.
EUROPEAN JOURNAL OF CANCER (2012)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
Tomasz Byrski et al.
BREAST CANCER RESEARCH (2012)
Triple negative breast cancer: unmet medical needs
Sumanta Kumar Pal et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists
Sunil Badve et al.
MODERN PATHOLOGY (2011)
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
Jens Huober et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Triple-Negative Breast Cancer Role of Specific Chemotherapy Agents
Steven J. Isakoff
CANCER JOURNAL (2010)
Ki67 in breast cancer: prognostic and predictive potential
Rinat Yerushalmi et al.
LANCET ONCOLOGY (2010)
Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999-2004
Carol A. Parise et al.
BREAST JOURNAL (2009)
Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study
William M. Sikov et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer
Emilio Bria et al.
LUNG CANCER (2009)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
Lisa A. Carey et al.
CLINICAL CANCER RESEARCH (2007)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
分享论文
